HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software.
The Wearable Imaging for Transforming Elderly Care (WITEC) collaborative research project aims to develop the world’s first wearable ultrasound imaging system for continuous, real-time monitoring and personalised diagnosis of chronic conditions such as hypertension and heart failure.
The tiny opaque tube that Yonghui Ding holds up to the light in his laboratory looks like a bit of debris from a dismantled ballpoint pen.
Researchers from the University of Windsor are using neutrons at the Department of Energy’s Oak Ridge National Laboratory to better understand symptoms associated with e-cigarette/vaping-associated lung injury (EVALI).
A cross-disciplinary research team has, for the first time, successfully applied NIR-II (1,000–3,000 nm) fluorescence video imaging during esophagectomy.
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.
As a result, significant drug exposures can be missed. Knowing what drugs are present is important because they can have unexpected effects on biology and health.
MIT researchers discover how an immune system molecule triggers neurons to shut down social behavior in mice modeling infection.
In a new leap for neurobiology and bioelectronics, Northwestern University scientists have developed a wireless device that uses light to send information directly to the brain—bypassing the body’s natural sensory pathways.
NES ZIONA, Israel, Dec. 8, 2025 /PRNewswire/ — EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world’s first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.